EGFR and cancer prognosis
EGFR and cancer prognosis
复制标题
DOI：
10.1016/s0959-8049(01)00231-3
复制
发表时间：
2001-09-01
影响因子：
8.4
通讯作者：
Harper, ME
中科院分区：
文献类型：
--
作者：
Nicholson, RI;Gee, JMW;Harper, ME
表皮生长因子受体（EGFR）（一种生长因子受体酪氨酸激酶）和;或其同源配体水平升高已被确定为多种癌症类型的常见组分，并似乎促进实体瘤生长。本文基于PubMed 1985年至2000年9月的文献，探讨EGFR表达与肿瘤预后的关系。超过200项研究被确定为分析了超过20000例患者的无复发间期或生存数据与EGFR水平的直接关系。数据分析显示，10种癌症类型均表达相对于正常组织升高的EGFR水平，并且已经进行了足够深入的研究，以便就EGFIR与患者前景之间的关联做出合理的判断。EGFR在头颈部、卵巢、宫颈等肿瘤中可作为强有力的预后指标。膀胱癌和食道癌。在这些癌症中，70%（52/74）的研究中EGFR表达增加与无复发率或总生存率降低相关。在胃癌、乳腺癌、子宫内膜癌和结直肠癌中，EGFR提供了更适度的预后信息，在52%（13/25）的研究中与不良生存率相关，而在非小细胞肺癌（NSCLC）中。EGFR表达很少（3/10项研究）与患者前景相关。然而. EGFR的真正预后意义可能被低估了，因为已发表的研究仅评估了总细胞EGFR水平，而不是受体的活化形式，并且未就患者群体或测定方法进行标准化。最后，重要的是要强调，在任何一种癌症类型中未能检测到EGFR的预后意义并不一定排除患者从抗EGFR治疗中获益。(C)2001爱思唯尔科技有限公司版权所有。
Elevated levels of the epidermal growth factor receptor (EGFR), a growth-factor-receptor tyrosine kinase, and;:or its cognate ligands have been identified as a common component of multiple cancer types and appear to promote solid tumour growth. This article examines the relationship between EGFR expression and cancer prognosis based on literature compiled on PubMed between 1985 and September 2000. More than 200 studies were identified that analysed relapse-free-interval or survival data directly in relation to EGFR levels in over 20000 patients. Analysis of the data showed that 10 cancer types both express elevated levels of EGFR relative to normal tissues and have been studied in sufficient depth to allow sound judgements to be made concerning the association between EGFIR and patient outlook. The EGFR was found to act as it strong prognostic indicator in head and neck, ovarian, cervical. bladder and oesophageal cancers. In these cancers, increased EGFR expression was associated with reduced recurrence-free or overall survival rates in 70% (52/74) of studies. In gastric, breast, endometrial and colorectal cancers, the EGFR provided more modest prognostic information, correlating to poor survival rates in 52% (13/25) of studies, while in non-small cell lung cancer (NSCLC). EGFR expression only rarely (3/10 studies) related to patient outlook. However. it is likely that the true prognostic significance of the EGFR has been underestimated as the published studies only assessed total cellular EGFR levels, rather than the activated form of the receptor, and were not standardised with regard to patient populations or assay methods. Finally, it is important to stress that failure to detect a prognostic significance for EGFR in any one cancer type does not necessarily preclude patients from benefiting from anti-EGFR therapies. (C) 2001 Elsevier Science Ltd. All rights reserved.